Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

New lemborexant efficacy and safety data unveiled

Publish date:: June 17, 2019

Key clinical point: Lemborexant effectively treated both sleep onset and sleep maintenance variables in men and women with insomnia.

Major finding: In both sexes, subject-reported sleep onset latency was significantly reduced versus that of placebo for lemborexant 5 mg and lemborexant 10 mg during the first 7 days and end of month 1 (P less than .05 for all comparisons).

Study details: A pooled analysis of data from 1,693 subjects enrolled in SUNRISE-1 and SUNRISE-2.

Disclosures: The research was supported by Eisai. Dr. Moline is an employee of the company.

Citation:

Moline M et al. Sleep 2019, Abstract 0368.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

DOACs look safe in elective endoscopic procedures,

Anorexia and diarrhea top list of GI symptoms in COVID-19 patients,

Must Reads in Sleep Medicine

Study links sleep meds and dementia risk in older adults,

Sleep apnea found to impact pain severity in younger adults,

OSA diagnoses not carried forward to the inpatient setting,

Screening algorithm safely selects patients for OSA treatment before bariatric surgery,

Study validates OSA phenotypes in Latinos,